Amedisys, Inc. (AMED) Reports Mixed Q3 Results; Cuts FY11 EPS Guidance; Announces Strategic Alignment, Mgmt Changes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts AMED Hot Sheet
Price: $100.99 --0%
Financial Fact:
Income tax expense: -6.69M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Income tax expense: -6.69M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Amedisys, Inc. (NASDAQ: AMED) reported Q3 EPS of $0.36, vs. the analyst estimate of $0.50. Revenue for the quarter came in at $374.9 million versus the consensus estimate of $372.06 million.
Also named Ronald Laborde as the company's new President. Dale Redman will transition to the company's CFO. Mike Snow will be leaving from the COO position.
Amedisys, Inc. sees FY2011 EPS of $1.90-$2.00, versus prior guidance of $2.20-$2.40 and the consensus of $2.30.
Also named Ronald Laborde as the company's new President. Dale Redman will transition to the company's CFO. Mike Snow will be leaving from the COO position.
Amedisys, Inc. sees FY2011 EPS of $1.90-$2.00, versus prior guidance of $2.20-$2.40 and the consensus of $2.30.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ingersoll Rand names two new segment presidents, CEO gets new deal
- Gates Industrial Corporation plc (GTES) Tops Q3 EPS by 4c ; Offers Guidance
- Dominion Energy (D) Tops Q3 EPS by 9c, Beats on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Guidance, Management Changes, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
